QUELL

Serial Number 88372290
Registration 6077717
700

Registration Progress

Application Filed
Apr 4, 2019
Under Examination
Approved for Publication
Mar 31, 2020
Published for Opposition
Mar 31, 2020
Registered
Jun 16, 2020

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2020-06-16)
Due: Jun 16, 2026 319 days

Trademark Image

QUELL

Basic Information

Serial Number
88372290
Registration Number
6077717
Filing Date
April 4, 2019
Registration Date
June 16, 2020
Published for Opposition
March 31, 2020
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 16, 2020
Registration
Registered
Classes
005 040 042 044

Rights Holder

Quell Therapeutics Limited

99
Address
3rd Floor, Translation & Innovation Hub
84 Wood Lane
London W120BZ
GB

Ownership History

Quell Therapeutics Limited

Original Applicant
99
London GB

Quell Therapeutics Limited

Owner at Publication
99
London GB

Quell Therapeutics Limited

Original Registrant
99
London GB

Legal Representation

Attorney
Steven T. Shelton

USPTO Deadlines

Next Deadline
319 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-06-16)
Due Date
June 16, 2026
Grace Period Ends
December 16, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

32 events
Date Code Type Description Documents
Jun 16, 2025 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jan 25, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jan 25, 2023 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jan 25, 2023 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jan 25, 2023 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Loading...
Jan 25, 2023 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jan 25, 2023 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jun 16, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Mar 31, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 31, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 11, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 25, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 25, 2020 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Feb 25, 2020 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Feb 25, 2020 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Feb 25, 2020 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Feb 13, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 13, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 13, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 23, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 23, 2020 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jan 23, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 30, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 30, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 30, 2019 ALIE A ASSIGNED TO LIE Loading...
Dec 9, 2019 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 24, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 24, 2019 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 24, 2019 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 14, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 22, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 8, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and biological preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; veterinary preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for cell therapy, namely, preparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceutical, medical, and clinical preparations for use in treatment, amelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparations, namely, chimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management
Class 040
Manufacturing and processing pharmaceuticals for others; manufacturing and processing biological, biotechnological and biopharmaceutical preparations for others; processing of biological tissue, blood, cell, and genetic material for others; production and manufacture of viral vectors for others; production and manufacture of gene therapy products for others; custom manufacture of pharmaceutical and biological preparations for others; none of the foregoing having any relation to pain treatment or management
Class 042
advisory services relating to gene therapy and design; Scientific and technological services, namely, research and design in the field of T cells with an immunosuppressive phenotype and transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; industrial analysis and research in the field of cell therapy; medical and veterinary research services in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new therapies in the field of autoimmune, immunological disorders and to modulate the immune system; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; scientific and technological services, namely, design in the field of cell therapy; none of the foregoing having any relation to pain treatment or management
Class 044
Medical services; medical services in the field of immunology; medical services in the field of surgery; medical services in the field of autoimmune diseases and conditions; medical services, in the field of, tissue transplant surgery; collection and preservation of biological tissue, blood, cells and genetic materials; medical diagnosis of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; Medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; providing information and data for diagnosis and medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; gene and nucleic acid delivery or modification for therapeutic purposes; medical treatment, namely, administering cell or gene therapies; advisory services in the field of health as it relates to cell or gene therapy; medical advisory services relating to cell or gene therapy; none of the foregoing having any relation to pain treatment or management

Classification

International Classes
005 040 042 044